MY182773A - Method for indicating a presence or non-presence of aggressive prostate cancer - Google Patents
Method for indicating a presence or non-presence of aggressive prostate cancerInfo
- Publication number
- MY182773A MY182773A MYPI2015701578A MYPI2015701578A MY182773A MY 182773 A MY182773 A MY 182773A MY PI2015701578 A MYPI2015701578 A MY PI2015701578A MY PI2015701578 A MYPI2015701578 A MY PI2015701578A MY 182773 A MY182773 A MY 182773A
- Authority
- MY
- Malaysia
- Prior art keywords
- prostate cancer
- aggressive prostate
- indicating
- various forms
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Medical Informatics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1251312 | 2012-11-20 | ||
| SE1350600 | 2013-05-16 | ||
| PCT/EP2013/074259 WO2014079865A1 (en) | 2012-11-20 | 2013-11-20 | Method for indicating a presence or non-presence of aggressive prostate cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY182773A true MY182773A (en) | 2021-02-05 |
Family
ID=49619938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2015701578A MY182773A (en) | 2012-11-20 | 2013-11-20 | Method for indicating a presence or non-presence of aggressive prostate cancer |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10431326B2 (enExample) |
| EP (2) | EP2922967B1 (enExample) |
| JP (2) | JP2016503301A (enExample) |
| KR (1) | KR20150110477A (enExample) |
| AU (1) | AU2013349801B2 (enExample) |
| BR (1) | BR112015011359B1 (enExample) |
| CA (2) | CA2891392C (enExample) |
| DK (1) | DK2922967T3 (enExample) |
| ES (1) | ES2667326T3 (enExample) |
| IL (1) | IL238724A0 (enExample) |
| MY (1) | MY182773A (enExample) |
| RU (1) | RU2675370C2 (enExample) |
| WO (1) | WO2014079865A1 (enExample) |
| ZA (1) | ZA201503460B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3312749T3 (fi) | 2012-03-05 | 2024-05-31 | Oy Arctic Partners Ab | Menetelmiä ja laitteita eturauhassyövän riskin ja eturauhasen tilavuuden ennustamiseen |
| CA2891394C (en) | 2012-11-20 | 2023-03-14 | Phadia Ab | Prognostic method for individuals with prostate cancer |
| FI3117216T3 (fi) | 2014-03-11 | 2023-04-27 | Phadia Ab | Menetelmä kiinteäkasvaimisen syövän tunnistamiseksi |
| MY192513A (en) | 2014-03-28 | 2022-08-24 | Opko Diagnostics Llc | Compositions and methods related to diagnosis of prostate cancer |
| US12326453B2 (en) * | 2014-03-28 | 2025-06-10 | Opko Diagnostics, Llc | Compositions and methods for active surveillance of prostate cancer |
| WO2016160545A1 (en) | 2015-03-27 | 2016-10-06 | Opko Diagnostics, Llc | Prostate antigen standards and uses thereof |
| US9858665B2 (en) * | 2015-04-03 | 2018-01-02 | Regents Of The University Of Minnesota | Medical imaging device rendering predictive prostate cancer visualizations using quantitative multiparametric MRI models |
| EP3287786A3 (en) * | 2015-04-29 | 2018-03-21 | Opko Diagnostics, LLC | Compositions and methods for active surveillance of prostate cancer |
| WO2017164699A1 (ko) * | 2016-03-24 | 2017-09-28 | 서울대학교병원 (분사무소) | 전립선암과 관련된 단일염기다형성 및 이를 이용한 유전 위험도 점수의 개발 |
| DK3270163T3 (en) * | 2016-07-15 | 2018-11-19 | Proteomedix Ag | PROCEDURE FOR DETECTING PROTEINS IN HUMAN SAMPLES AND APPLICATIONS OF SUCH PROCEDURES |
| WO2018141828A1 (en) | 2017-02-01 | 2018-08-09 | Phadia Ab | Method for indicating a presence or non-presence of prostate cancer in individuals with particular characteristics |
| KR102093453B1 (ko) * | 2018-01-08 | 2020-03-25 | (주)인실리코젠 | 체형 및 대사 감수성 snp 마커 및 진단정보 제공방법 |
| CN111712878A (zh) | 2018-01-22 | 2020-09-25 | 法迪亚股份公司 | 用于协调分析结果的方法 |
| IT201800021394A1 (it) * | 2018-12-28 | 2020-06-28 | Daniela Terracciano | Metodo in vitro per la diagnosi del cancro alla prostata |
| US11633146B2 (en) | 2019-01-04 | 2023-04-25 | Regents Of The University Of Minnesota | Automated co-registration of prostate MRI data |
| US11631171B2 (en) | 2019-01-10 | 2023-04-18 | Regents Of The University Of Minnesota | Automated detection and annotation of prostate cancer on histopathology slides |
| CN109628564B (zh) * | 2019-02-25 | 2022-02-01 | 北京市理化分析测试中心 | 一种用于检测snp多态性的引物组和利用引物组检测snp多态性的方法 |
| KR102068667B1 (ko) * | 2019-02-28 | 2020-01-21 | 주식회사 프로카젠 | 전립선암 유전위험점수 산출장치, 산출방법 및 이의 기록매체 |
| KR102371654B1 (ko) * | 2019-02-28 | 2022-03-08 | 주식회사 프로카젠 | 유전 변이의 개수에 따른 예측력을 고려한 전립선암 유전위험점수 산출장치, 산출방법 및 이의 기록매체 |
| KR102068666B1 (ko) * | 2019-02-28 | 2020-02-11 | 주식회사 프로카젠 | 인종 별 전립선암 유전위험점수 산출장치, 산출방법 및 이의 기록매체 |
| KR102371655B1 (ko) * | 2019-02-28 | 2022-03-08 | 주식회사 프로카젠 | 각 유전 변이 정보에 개별적인 가중치를 부여한 전립선암 유전위험점수 산출장치, 산출방법 및 이의 기록매체 |
| IT202000029948A1 (it) * | 2020-12-04 | 2022-06-04 | Nib Biotec S R L | Metodo per la diagnosi di tumore alla prostata in pazienti in differente fascia di età |
| JP7641532B2 (ja) * | 2020-08-28 | 2025-03-07 | 国立研究開発法人理化学研究所 | 前立腺がんの検査方法 |
| GB2599198B (en) * | 2021-06-15 | 2022-12-07 | A3P Biomedical Ab | A method for determining an appropriate time interval for further diagnostic testing for prostate cancer |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030219840A1 (en) | 2002-05-24 | 2003-11-27 | Mikolajczyk Stephen D. | Method of analyzing proenzyme forms of prostate specific antigen in serum to improve prostate cancer detection |
| FR2934698B1 (fr) | 2008-08-01 | 2011-11-18 | Commissariat Energie Atomique | Procede de prediction pour le pronostic ou le diagnostic ou la reponse therapeutique d'une maladie et notamment du cancer de la prostate et dispositif permettant la mise en oeuvre du procede. |
| WO2010081240A1 (en) | 2009-01-19 | 2010-07-22 | Miraculins Inc. | Diagnostic assays for prostate cancer using psp94 and psa biomarkers |
| US20120121618A1 (en) | 2009-02-12 | 2012-05-17 | Dana-Farber Cancer Institute, Inc. | Predicting And Treating Prostate Cancer |
| WO2011150515A1 (en) | 2010-06-01 | 2011-12-08 | Universite Laval | Prognostic markers for prostate cancer recurrence |
| US9732389B2 (en) * | 2010-09-03 | 2017-08-15 | Wake Forest University Health Sciences | Methods and compositions for correlating genetic markers with prostate cancer risk |
| US20120202888A1 (en) | 2010-10-08 | 2012-08-09 | The Brigham And Women's Hospital, Inc. | Biomarkers of prostate cancer and predicting mortality |
| US20120150032A1 (en) * | 2010-12-13 | 2012-06-14 | Julius Gudmundsson | Sequence Variants Associated with Prostate Specific Antigen Levels |
| JP2015524052A (ja) * | 2012-05-16 | 2015-08-20 | ファディア・アクチボラゲットＰｈａｄｉａ ＡＢ | 前立腺癌の存在または不存在の提示方法 |
| CA2891394C (en) | 2012-11-20 | 2023-03-14 | Phadia Ab | Prognostic method for individuals with prostate cancer |
-
2013
- 2013-11-20 JP JP2015542308A patent/JP2016503301A/ja active Pending
- 2013-11-20 RU RU2015124054A patent/RU2675370C2/ru active
- 2013-11-20 AU AU2013349801A patent/AU2013349801B2/en active Active
- 2013-11-20 EP EP13792689.5A patent/EP2922967B1/en active Active
- 2013-11-20 EP EP17210720.3A patent/EP3327146A1/en not_active Withdrawn
- 2013-11-20 MY MYPI2015701578A patent/MY182773A/en unknown
- 2013-11-20 US US14/443,970 patent/US10431326B2/en active Active
- 2013-11-20 BR BR112015011359-1A patent/BR112015011359B1/pt not_active IP Right Cessation
- 2013-11-20 ES ES13792689.5T patent/ES2667326T3/es active Active
- 2013-11-20 CA CA2891392A patent/CA2891392C/en active Active
- 2013-11-20 DK DK13792689.5T patent/DK2922967T3/en active
- 2013-11-20 KR KR1020157015113A patent/KR20150110477A/ko not_active Ceased
- 2013-11-20 CA CA3092807A patent/CA3092807C/en active Active
- 2013-11-20 WO PCT/EP2013/074259 patent/WO2014079865A1/en not_active Ceased
-
2015
- 2015-05-10 IL IL238724A patent/IL238724A0/en unknown
- 2015-05-18 ZA ZA2015/03460A patent/ZA201503460B/en unknown
-
2018
- 2018-10-04 JP JP2018189147A patent/JP2019049559A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HK1215594A1 (en) | 2016-09-02 |
| AU2013349801B2 (en) | 2019-03-07 |
| CA3092807A1 (en) | 2014-05-30 |
| EP2922967B1 (en) | 2018-01-03 |
| RU2015124054A (ru) | 2017-01-10 |
| DK2922967T3 (en) | 2018-04-16 |
| EP3327146A1 (en) | 2018-05-30 |
| WO2014079865A1 (en) | 2014-05-30 |
| US20150317431A1 (en) | 2015-11-05 |
| BR112015011359B1 (pt) | 2022-12-06 |
| AU2013349801A1 (en) | 2015-05-28 |
| CA2891392C (en) | 2020-11-03 |
| CA3092807C (en) | 2024-02-27 |
| RU2675370C2 (ru) | 2018-12-19 |
| EP2922967A1 (en) | 2015-09-30 |
| CA2891392A1 (en) | 2014-05-30 |
| KR20150110477A (ko) | 2015-10-02 |
| IL238724A0 (en) | 2015-06-30 |
| ES2667326T3 (es) | 2018-05-10 |
| BR112015011359A2 (pt) | 2017-07-11 |
| BR112015011359A8 (pt) | 2019-10-01 |
| JP2019049559A (ja) | 2019-03-28 |
| ZA201503460B (en) | 2018-11-28 |
| JP2016503301A (ja) | 2016-02-04 |
| US10431326B2 (en) | 2019-10-01 |
| CN105051206A (zh) | 2015-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY182773A (en) | Method for indicating a presence or non-presence of aggressive prostate cancer | |
| WO2013172779A3 (en) | Method for indicating the presence or non-presence of prostate cancer | |
| WO2014057357A3 (en) | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-maf | |
| WO2012045905A3 (es) | Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama | |
| WO2014140933A8 (en) | Method for the prognosis and treatment of cancer metastasis | |
| EA201590027A1 (ru) | Способы детекции заболеваний или состояний | |
| AU2013211850A8 (en) | Methods for profiling and quantitating cell-free RNA | |
| EP3683320A3 (en) | Mirna fingerprint in the diagnosis of lung cancer | |
| PH12018550037A1 (en) | Quencher containing water-soluble polymer-conjugated nanomaterial and use thereof | |
| IN2013CN01129A (enExample) | ||
| MY195999A (en) | Molecular Detection/Diagnosis Reagent for Tumor | |
| EP4604127A3 (en) | Methods and processes for non-invasive assessment of genetic variations | |
| WO2013025952A3 (en) | Methods and compositions for the treatment and diagnosis of breast cancer | |
| MX347895B (es) | Dispositivo y método para obtener y procesar lecturas de medición de un ser vivo. | |
| EP3236262A3 (en) | Surrogate functional diagnostics test for cancer | |
| ATE554389T1 (de) | Apex als marker für lungenkrebs | |
| IN2012DN04944A (enExample) | ||
| BR112016007864A2 (pt) | método para a prognose e tratamento de metástase de câncer | |
| WO2009083780A8 (en) | Breast cancer expression profiling | |
| EA201700123A1 (ru) | Способ прогнозирования варианта лекарственного препарата для лечения депрессии | |
| MY195045A (en) | Specific Biomarker Set For Non-Invasive Diagnosis of Liver Cancer | |
| MX359376B (es) | Metodo y kit para la determinacion de cobre libre en suero. | |
| EP2584045A4 (en) | METHOD FOR DETECTING COLORECTAL CANCER | |
| IN2015DN01646A (enExample) | ||
| BR112015022977A2 (pt) | métodos para predição de risco de metástase em melanoma cutâneo |